Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy

Josefina Marin, María Laura Acosta Felquer, Enrique R Soriano Rheumatology Unit, Internal Medical Serivces, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina Abstract: Certolizumab pegol (CZP) is a pegylated huma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marin J, Acosta Felquer ML, Soriano ER
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	certolizumab pegol tumor necrosis factor-α inhibitors ankylosing spondilitys non-radiographic axial spondyloarthritis efficacy safety Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/d7db2130f257427ab00260fb3fb0170b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d7db2130f257427ab00260fb3fb0170b
record_format	dspace
spelling	oai:doaj.org-article:d7db2130f257427ab00260fb3fb0170b2021-12-02T11:22:16ZSpotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy1179-156Xhttps://doaj.org/article/d7db2130f257427ab00260fb3fb0170b2018-05-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-certolizumab-pegol-in-the-treatment-of-axial-spondyloarth-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XJosefina Marin, María Laura Acosta Felquer, Enrique R Soriano Rheumatology Unit, Internal Medical Serivces, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina Abstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, preventing complement fixation and cytotoxicity mediated by antibody; CZP does not actively cross the placenta, unlike other TNFi. RAPID-axSpA study is a Phase III trial conducted in patients with AS and nr-axSpA as double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Of a total of 325 patients recruited, 107 patients were assigned to placebo and 218 patients to CZP (111 to CZP 200 mg Q2W, 107 to CZP 400 mg Q4W). Improvements in axial involvement, joint involvement, enthesitis and quality of life were reported in patients treated with CZP. Safety profile was like that reported for other TNFi in axSpA patients. In this article, we summarized the pharmacology and we reviewed the efficacy and tolerability of this drug for the treatment of axSpA. Some special considerations of CZP during pregnancy are included. CZP, the latest TNFi to be approved, showed efficacy in all manifestations of AS and nr-axSpA. Keywords: certolizumab pegol, tumor necrosis factor-α inhibitors, ankylosing spondylitis, non-radiographic axial spondyloarthritis, efficacy, safetyMarin JAcosta Felquer MLSoriano ERDove Medical Pressarticlecertolizumab pegoltumor necrosis factor-α inhibitorsankylosing spondilitysnon-radiographic axial spondyloarthritisefficacysafetyDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 10, Pp 33-41 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	certolizumab pegol tumor necrosis factor-α inhibitors ankylosing spondilitys non-radiographic axial spondyloarthritis efficacy safety Diseases of the musculoskeletal system RC925-935
spellingShingle	certolizumab pegol tumor necrosis factor-α inhibitors ankylosing spondilitys non-radiographic axial spondyloarthritis efficacy safety Diseases of the musculoskeletal system RC925-935 Marin J Acosta Felquer ML Soriano ER Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
description	Josefina Marin, María Laura Acosta Felquer, Enrique R Soriano Rheumatology Unit, Internal Medical Serivces, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina Abstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, preventing complement fixation and cytotoxicity mediated by antibody; CZP does not actively cross the placenta, unlike other TNFi. RAPID-axSpA study is a Phase III trial conducted in patients with AS and nr-axSpA as double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Of a total of 325 patients recruited, 107 patients were assigned to placebo and 218 patients to CZP (111 to CZP 200 mg Q2W, 107 to CZP 400 mg Q4W). Improvements in axial involvement, joint involvement, enthesitis and quality of life were reported in patients treated with CZP. Safety profile was like that reported for other TNFi in axSpA patients. In this article, we summarized the pharmacology and we reviewed the efficacy and tolerability of this drug for the treatment of axSpA. Some special considerations of CZP during pregnancy are included. CZP, the latest TNFi to be approved, showed efficacy in all manifestations of AS and nr-axSpA. Keywords: certolizumab pegol, tumor necrosis factor-α inhibitors, ankylosing spondylitis, non-radiographic axial spondyloarthritis, efficacy, safety
format	article
author	Marin J Acosta Felquer ML Soriano ER
author_facet	Marin J Acosta Felquer ML Soriano ER
author_sort	Marin J
title	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
title_short	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
title_full	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
title_fullStr	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
title_full_unstemmed	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
title_sort	spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/d7db2130f257427ab00260fb3fb0170b
work_keys_str_mv	AT marinj spotlightoncertolizumabpegolinthetreatmentofaxialspondyloarthritisefficacysafetyandplaceintherapy AT acostafelquerml spotlightoncertolizumabpegolinthetreatmentofaxialspondyloarthritisefficacysafetyandplaceintherapy AT sorianoer spotlightoncertolizumabpegolinthetreatmentofaxialspondyloarthritisefficacysafetyandplaceintherapy
_version_	1718395967139479552

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy

Ejemplares similares